Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Nikolaos, Ziras"'
Autor:
Stefania Kokkali, Emmanouil Saloustros, Dimitra Stefanou, Paris Makrantonakis, Nikolaos Kentepozidis, Ioannis Boukovinas, Nikolaos Xenidis, Panagiotis Katsaounis, Alexandros Ardavanis, Nikolaos Ziras, Athina Christopoulou, George Rigas, Kostas Kalbakis, Nikolaos Vardakis, Christos Emmanouilides, Ilias Athanasiadis, Athanassios Anagnostopoulos, Dora Hatzidaki, Efthimios Prinarakis, Foteini Simopoulou, Athanasios Kotsakis, Vassilis Georgoulias
Publikováno v:
Current Oncology, Vol 29, Iss 2, Pp 1237-1251 (2022)
Front-line bevacizumab (BEV) in combination with taxanes offers benefit in progression-free survival (PFS) in metastatic breast cancer (mBC). The medical records of mBC patients, treated with front-line BEV-based chemotherapy, were retrospectively re
Externí odkaz:
https://doaj.org/article/c982903354104203bb48bb3d0972f59f
Autor:
Athanasios, Alexopoulos, Charisios, Karanikiotis, Alexandros, Ardavanis, Ioannis, Boukovinas, Parisios, Makrantonakis, Christos, Papadimitriou, Athanasios, Athanasiadis, Anastasios, Boutis, Stylianos, Giassas, Stylianos, Kakolyris, Georgios, Koumakis, Konstantinos, Papazisis, Adamantia, Psyrri, Nikolaos, Ziras, Sofia, Baka, Nikolaos, Kentepozidis, Vasiliki, Michalaki
Publikováno v:
Anticancer Research. 42:1031-1041
This study aimed to provide real-world safety and effectiveness data of everolimus (EVE) plus exemestane (EXE) in estrogen receptor positive/human epidermal growth factor receptor 2 negative (ERThis prospective observational study was conducted by 19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f15efa37230a1b0448c0ed9618c5ef88
https://doi.org/10.21873/anticanres.15564
https://doi.org/10.21873/anticanres.15564
Autor:
Christos Kosmas, Ioannis Kalantzis, Kitty Pavlakis, Harikleia Gakiopoulou, Konstantinos Gkoumas, Afroditi Nonni, K Miltiadou, Nikolaos Ziras, Eumorphia-Maria Delicha
Publikováno v:
World Journal of Clinical Cases
BACKGROUND The differences in histopathology and molecular biology between right colon cancer (RCC) and left colon cancer (LCC) were first reported in the literature by Bufill in 1990. Since then, a large number of studies have confirmed their differ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fda008b7a2ead944fd7cdd37ba45e88d
https://doi.org/10.12998/wjcc.v8.i8.1424
https://doi.org/10.12998/wjcc.v8.i8.1424
Autor:
Stefania Kokkali, Emmanouil Saloustros, Dimitra Stefanou, Paris Makrantonakis, Nikolaos Kentepozidis, Ioannis Boukovinas, Nikolaos Xenidis, Panagiotis Katsaounis, Alexandros Ardavanis, Nikolaos Ziras, Athina Christopoulou, George Rigas, Kostas Kalbakis, Nikolaos Vardakis, Christos Emmanouilides, Ilias Athanasiadis, Athanassios Anagnostopoulos, Dora Hatzidaki, Efthimios Prinarakis, Foteini Simopoulou, Athanasios Kotsakis, Vassilis Georgoulias
Publikováno v:
Current Oncology; Volume 29; Issue 2; Pages: 1237-1251
Front-line bevacizumab (BEV) in combination with taxanes offers benefit in progression-free survival (PFS) in metastatic breast cancer (mBC). The medical records of mBC patients, treated with front-line BEV-based chemotherapy, were retrospectively re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d912d22acc3a1f5d3ceb8791b527d9c
https://pubmed.ncbi.nlm.nih.gov/35200604
https://pubmed.ncbi.nlm.nih.gov/35200604
Autor:
Athina Christopoulou, Alexandros Ardavanis, Christos Papandreou, Georgios Koumakis, Georgios Papatsimpas, Pavlos Papakotoulas, Nikolaos Tsoukalas, Charalambos Andreadis, Georgios Samelis, Pavlos Papakostas, Gerasimos Aravantinos, Nikolaos Ziras, Maria Souggleri, Charalambos Kalofonos, Epameinondas Samantas, Paris Makrantonakis, Georgios Pentheroudakis, Athanasios Athanasiadis, Helen Stergiou, Alexandros Bokas, Anastasios Grivas, Elli-Sofia Tripodaki, Ioannis Varthalitis, Eleni Timotheadou, Ioannis Boukovinas
Publikováno v:
Oncology letters. 23(4)
Thromboprophylaxis, as a preventive measure for cancer-associated thrombosis (CAT), may be beneficial for patients with active cancer and high-risk for thrombosis. The present post hoc analysis include a total of 407 patients enrolled in the Greek Ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25abafd45d0117bc858394f67d635f21
https://pubmed.ncbi.nlm.nih.gov/35251346
https://pubmed.ncbi.nlm.nih.gov/35251346
Autor:
Nikolaos Ziras, C. Kalofonos, Christos N. Papandreou, Pavlos Papakotoulas, Ioannis Boukovinas, Georgios Koumakis, Georgios Samelis, Helen Stergiou, Eleni Timotheadou, Evangelos Bournakis, Athina Christopoulou, Georgios Papatsimpas, Athanasios Athanasiadis, Gerasimos Aravantinos, Alexandros Bokas, Alexandros Ardavanis, Paris Makrantonakis, Ioannis Varthalitis, Maria Souggleri, Pavlos Papakostas, Epameinondas Samantas, Charalambos Andreadis, Nikolaos Tsoukalas, Anastasios Grivas, Sofia Tripodaki, Georgios Pentheroudakis
Publikováno v:
Anticancer Research. 40:305-313
Background Cancer-associated thrombosis (CAT), the second leading cause of death in patients with cancer can be treated with low molecular weight heparin (LMWH) according to guidelines. Patients and methods A multicenter prospective observational stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d297226a7d59f608becc1a78c7d9c8ab
https://doi.org/10.21873/anticanres.13954
https://doi.org/10.21873/anticanres.13954
Real-World Data on Thromboprophylaxis in Active Cancer Patients: Where Are We? Are We Getting There?
Autor:
Evangelos Bournakis, Athanasios Athanasiadis, Epameinondas Samantas, Gerasimos Aravantinos, Christos N. Papandreou, Georgios Samelis, Charalambos Andreadis, Maria Souggleri, Anastasios Grivas, Elli-Sofia Tripodaki, Georgios Koumakis, Nikolaos Ziras, Helen Stergiou, Eleni Timotheadou, Nikolaos Tsoukalas, Georgios Papatsimpas, Ioannis Varthalitis, Paris Makrantonakis, Alexandros Bokas, C. Kalofonos, Ioannis Boukovinas, Alexandros Ardavanis, Pavlos Papakostas, P. Papakotoulas, Athina Christopoulou, Georgios Pentheroudakis
Publikováno v:
Cancers, Vol 12, Iss 1907, p 1907 (2020)
Cancers
Volume 12
Issue 7
Cancers
Volume 12
Issue 7
Background: Cancer patients are at high risk for cancer-associated thrombosis (CAT). CAT is the second leading cause of death in these patients but it can be preventable with thromboprophylaxis. Patients and Methods: An observational, prospective, mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c69b406e149627e5605c25268fa6004
https://www.mdpi.com/2072-6694/12/7/1907
https://www.mdpi.com/2072-6694/12/7/1907
Autor:
G. Vorgias, D. Symeonidis, P. Manikis, G. Papageorgiou, C. Kosmas, E. Lianos, N. Charalambakis, Nikolaos Ziras, S. Xynogalos
Publikováno v:
Annals of Oncology. 31:S1049-S1050
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00f3114082776ffb39f00359e7acdb01
https://doi.org/10.1016/j.annonc.2020.08.1465
https://doi.org/10.1016/j.annonc.2020.08.1465
Autor:
C. Kourousis, C. Christofyllakis, M. Vaslamatzis, G. Papadopoulos, John Souglakos, A. Christopoulou, Iliada Bompolaki, Athanasios Karampeazis, E Athanasiadis, P. Makrantonakis, Nikolaos Ziras, Nikolaos K. Kentepozidis, D. Mavroudis, U Katopodi, A Anagnosopoulos, Alexandros Ardavanis, A Kalisperi, S Xynogalos, Christos Emmanouilides, Georgoulias, I. Boukovinas, Nikos Androulakis, S. Kakolyris, Athanasios Athanasiadis, E. Prinarakis
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 30(8)
Background The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) aimed to investigate whether a 3 months (3M) of oxaliplatin/fluoropyrimidine-based adjuvant chemotherapy (CT) is non-inferior to the 6-month (6M) administration in 3-yea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82eb505ebbfcbe0a315dd7c78fd65349
https://pubmed.ncbi.nlm.nih.gov/31228203
https://pubmed.ncbi.nlm.nih.gov/31228203
Autor:
Emmanouil Saloustros, Nikolaos Ziras, S. Kakolyris, V. Georgoulias, Nikolaos K. Kentepozidis, D. Mavroudis, N. Malamos, Athanasios Athanasiadis, P. Katsaounis, I. Boukovinas, P. Papakotoulas, Alexios Matikas
Publikováno v:
Annals of Oncology. 27:1873-1878
Background: Sequential administration of anthracycline and taxane is the current standard of care adjuvant regimen for node-positive early breast cancer. Due to long-term toxicity concerns, anthracycline-free regimens have been developed. We compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3d7d3b6e3f0dbaa51cc66fde0f48cb9
https://doi.org/10.1093/annonc/mdw274
https://doi.org/10.1093/annonc/mdw274